BCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)

N/A

Report date: 2024/10/18 20:00:35

Base Information

Drug NameBCMA-GPRC5D CAR-T cells Therapy (Shenzhen University General Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-BCMAG-protein coupled receptor family C group 5member D modulators
TargetsB-cell maturation proteinG-protein coupled receptor family C group 5member D
Therapy Area/IndicationsMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShenzhen University General Hospital
China Registration ClassN/A

Develop Information

Active CompaniesShenzhen University General Hospital
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A